A natural anti-inflammatory enone fatty acid inhibits angiogenesis by attenuating nuclear factor-κB signaling in vascular endothelial cells

International Journal of Oncology

Volumn 38, Issue 2, 2011, Pages 493-501

  Furuno, Ayana ^a   Watari, Kosuke ^a   Mamiyo, Nakamura ^a   Yuichi, Fukunaga ^a   Jung, Jee H ^b   Ono, Mayumi ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b Pusan National University   (South Korea)

Author keywords

Anti angiogenesis; Enone fatty acid; Nuclear factor B

Indexed keywords

10 UNDECENOIC ACID; 9 OXOOCTADEC 10 ENOIC ACID; ALPHA CHEMOKINE; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CELL MIGRATION; CELL PROLIFERATION; DRUG MECHANISM; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IC 50; MALE; NONHUMAN; PRIORITY JOURNAL; UMBILICAL VEIN ENDOTHELIAL CELL;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTI-INFLAMMATORY AGENTS; BLOTTING, WESTERN; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FATTY ACIDS; HUMANS; MACROCYCLIC COMPOUNDS; MALE; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; NF-KAPPA B; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; UMBILICAL VEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 78651252008     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2010.856     Document Type: Article

References (35)

1. Costa C, Incio J and Soares R: Angiogenesis and chronic inflammation: cause or consequence? Angiogenesis 10: 149-166, 2007.
2. Ono M: Molecular links between tumor angiogenesis and inflammation: inflammatory stimuli of macrophages and cancer cells as targets for therapeutic strategy. Cancer Sci 99: 1501-1506, 2008.
3. Ryuto M, Ono M, Izumi H, Yoshida S, Weich HA, Kohno K and Kuwano M: Induction of vascular endothelial growth factor by tumor necrosis factor α in human glioma cells. J Biol Chem 271: 28220-28228, 1996.
4. Shono T, Ono M, Izumi H, et al: Involvement of the transcription factor NF-κB in tubular morphogenesis of human microvascular endothelial cells by oxidative stress. Mol Cell Biol 16: 4231-4239, 1996.
5. Yoshida S, Ono M, Shono T, Izumi H, Ishibashi T, Suzuki H and Kuwano M: Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Mol Cell Biol 17: 4015-4023, 1997.
6. Saijo Y, Tanaka M, Miki M, et al: Proinflammatory cytokine IL-1β promotes tumor growth of Lewis lung carcinoma by induction of angiogenic factors: in vivo analysis of tumorstromal interaction. J Immunol 169: 469-475, 2002.
7. Voronov E, Shouval DS, Krelin Y, et al: IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci USA 100: 2645-2650, 2003. (Pubitemid 36297552)
8. Torisu H, Ono M, Kiryu H, et al: Macrophage infiltration correlates with tumor stage and angiogenesis in human malignant melanoma: possible involvement of TNFα and IL-1α. Int J Cancer 85: 182-188, 2000. (Pubitemid 30023065)
9. Kuwano T, Nakao S, Yamamoto H, Tsuneyoshi M, Yamamoto T, Kuwano M and Ono M: Cyclooxygenase 2 is a key enzyme for inflammatory cytokine-induced angiogenesis. FASEB J 18: 300-310, 2004. (Pubitemid 38186249)
10. Nakao S, Kuwano T, Tsutsumi-Miyahara C, et al: Infiltration of COX-2-expressing macrophages is a prerequisite for IL-1β-induced neovascularization and tumor growth. J Clin Invest 115: 2979-2991, 2005.
11. Kimura YN, Watari K, Fotovati A, et al: Inflammatory stimuli from macrophages and cancer cells synergistically promote tumor growth and angiogenesis. Cancer Sci 98: 2009-2018, 2007.
12. Watari K, Nakao S, Fotovati A, et al: Role of macrophages in inflammatory lymphangiogenesis: Enhanced production of vascular endothelial growth factor C and D through NF-κB activation. Biochem Biophys Res Commun 377: 826-831, 2008.
13. Dang HT, Lee HJ, Yoo ES, et al: Anti-inflammatory constituents of the red alga Gracilaria verrucosa and their synthetic analogues. J Nat Prod 71: 232-240, 2008.
14. Hirata A, Ogawa S, Kometani T, Kuwano T, Naito S, Kuwano M and Ono M: ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res 62: 2554-2560, 2002.
15. Gotink KJ and Verheul HM: Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? Angiogenesis 13: 1-14, 2010.
16. Llovet JM and Bruix J: Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48: 1312-1327, 2008.
17. Jubb AM, Hurwitz HI, Bai W, et al: Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol 24: 217-227, 2006.
18. Ferrara N, Hillan KJ, Gerber HP and Novotny W: Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3: 391-400, 2004. (Pubitemid 38618122)
19. Wilhelm SM, Carter C, Tang L, et al: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64: 7099-7109, 2004.
20. Mendel DB, Laird AD, Xin X, et al: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9: 327-337, 2003.
21. Coussens LM and Werb Z: Inflammation and cancer: Nature 420: 860-867, 2002.
22. Polyak K, Haviv I and Campbell IG: Co-evolution of tumor cells and their microenvironment. Trends Genet 25: 30-38, 2008.
23. Grosjean J, Kiriakidis S, Reilly K, Feldmann M and Paleolog E: Vascular endothelial growth factor signaling in endothelial cell survival: A role of NF-κB. Biochem Biophys Res Commun 340: 984-994, 2006.
24. Zachary I: VEGF signaling: integration and multi-tasking in endothelial cell biology. Biochem Soc Trans 31: 1171-1177, 2003.
25. Zandi E, Rothwarf DM, Delhase M, Hayakawa M and Karin M: The IκB kinase complex (IKK) contains two kinase subunits, IKKα and IKKβ, necessary for IκB phosphorylation and NF-κB activation. Cell 91: 243-252, 1997.
26. Adhikari A, Xu M and Chen ZJ: Ubiquitin-mediated activation of TAK1 and IKK. Oncogene 26: 3214-3226, 2007.
27. Strieter RM, Polverini PJ, Kunkel SL, et al: The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem 270: 27348-27357, 1995.
28. Matsuo Y, Raimond M, Woodward TA, et al: CXC-chemokine/CXCR2 biological axis promotes angiogenesis in vitro and in vivo in pancreatic cancer. Int J Cancer 125: 1027-1037, 2009.
29. Sica A, Schioppa T, Mantovani A and Allavena P: Tumor-associated macrophages are a distinct M2 polarised population promoting tumor progression: Potentioal targets of anti-cancer therapy. Eur J Cancer 42: 717-727, 2006.
30. Sica A, Rubino L, Mancino A, et al: Targeting tumor-associated macrophages. Expert Opin Ther Targets 11: 1219-1229, 2007.
31. Sica A, Allavena P and Mantovani A: Cancer related inflammation: The macrophage connection. Cancer Lett 267: 204-215, 2008.
32. Yoshimura A: Signal transduction of inflammatory cytokines and tumor development. Cancer Sci 97: 439-447, 2006.
33. Hiraoka K, Zenmyo M and Watari K: Inhibition of bone and muscle metastases of lung cancer cells by a decrease in the number of monocytes/macrophages. Cancer Sci 99: 1595-1602, 2008.
34. Miao C, Du J, Dang HT, et al: Apoptotic activity of fatty acid derivatives may correlate with their inhibition of DNA replication. Int J Oncol 33: 1291-1298, 2008.
35. Lee HJ, Dang HT, Kang GJ, et al: Two enone fatty acids isolated from Gracilaria verrucosa suppress the production of inflammatory mediators by down-regulating NF-κB and STAT1 activity in lipopolysaccharide-stimulated RAW264.7 cells. Arch Pharm Res 32: 453-462, 2009.